Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms...
Na minha lista:
| Udgivet i: | Curr Control Trials Cardiovasc Med |
|---|---|
| Principais autores: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2001
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC59641/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11806792/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/cvm-2-4-171 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|